anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Povidone iodine
Trial phase: Not Applicable
SMILES: C=CN1CCCC1=O.II
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 120
Group description: Standard Aseptic Technique:

Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops.

Standard Aseptic Technique: Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
Eligibility criteria:
Inclusion Criteria:

Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given in either Dr. Fan's clinic using povidone-iodine and post-injection topical ciprofloxacin 0.3% 4x daily for 3 days, or in Dr. Rauser's clinic where povidone-iodine only is applied to the injection site and conjunctival fornix but no post-injection antibiotics are given.

Exclusion Criteria:

Administration of anti-VEGF agents outside of Dr. Fan's or Dr. Rauser's clinics
Intraocular surgery
Use of topical antibiotics other than ciprofloxacin 0.3%
Infections of the eye or ocular adnexa within the last 3 months
Use of oral antibiotics within the last 30 days
Contact lens wear.
Intervention: Emricasan
Trial phase: Phase 2
SMILES: C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: 25 mg BID of IDN-6556 (Baseline-Month 3).
Eligibility criteria:
Inclusion Criteria:

Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study
Clinical, radiological, or biochemical evidence of liver cirrhosis
Model for End-Stage Liver Disease (MELD) Score of 11 to 18 during the Screening period
Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug.

Exclusion Criteria:

Known infection with human immunodeficiency virus (HIV)
Auto-immune hepatitis
Subjects with evidence of uncontrolled infection, defined as persistent bacterial culture positivity despite adequate antibiotic therapy
HCV infected subjects who are receiving or plan to receive anti-viral therapy during the study
Untreated esophageal varices with high risk stigmata for hemorrhage
Variceal hemorrhage within 3 months of Screening
Ascites not adequately controlled on stable background medication
Other non-liver organ failure
Child-Pugh score of 10-15 (Child-Pugh C classification)
Use of vasoactive drugs (at or within 3 months of Screening) that may impair hepatic blood flow

Change in dose or regimen within 3 months of Screening of:

Fibrates or statins
Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
Use of chronic anticoagulation therapy including but not limited to Vitamin K/Factor Xa antagonists/inhibitors

Use of the following drugs within 2 months of Screening:

Systemic corticosteroids
Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
Concomitant pancreatitis
Active inflammatory bowel disease
Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)
Subjects with active or history of malignancies other than hepatocellular carcinoma (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years
Intervention: Glycerin
Trial phase: Not Applicable
ATC code: A06AG04 | A06AX01
SMILES: OCC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Current standard of care for treatment of resistant partial thickness rotator cuff tears

Subacromial steroid bursal injection: Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
Eligibility criteria:
Inclusion Criteria:

subjects between ages 19 to 75, both male and female
radiologic imaging which can include either magnetic resonance imaging (MRI) or ultrasound (US) consistent with partial thickness rotator cuff tears of any degree except for full thickness tears
Failed a trial of physical therapy of at least 4 weeks

Exclusion Criteria:

Full thickness tears (well documented need for surgical correction)
sensory or neurologic complaint affecting the shoulder of interest
Coagulation disorder, platelet disorder
Pregnancy: Pregnancy test will be performed on women of childbearing age prior to their participation in the interventional portion of the study
Any major systemic illness such as ongoing infection or any condition that requires strict anti-platelet or anticoagulation therapy
Prior surgery to either cervical spine or shoulder
Active military
Injury part of worker compensation claim
Intervention: Dexmedetomidine
Trial phase: Phase 3
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 75
Group description: In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).

Dexmedetomidine: intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
Eligibility criteria:
Inclusion Criteria:

Children older than 5yrs and weighing more than 20kg , who are scheduled for ambulatory dental rehabilitation at Batson operating rooms.
ASA classification 1 or 2

Exclusion Criteria

Known allergy to midazolam, dexmedetomidine,morphine, fentanyl, sevoflurane and propofol.
uncorrected congenital heart disease or history of cardiac arrhythmia,
children at risk for airway obstruction (OSA or cranio facial syndrome),
pregnant minors
Intervention: Guanfacine
Trial phase: Not Applicable
ATC code: C02AC02
SMILES: N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 38
Group description: Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.

Guanfacine: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Eligibility criteria:
Inclusion Criteria:

ADHD Participants:

The participant satisfies Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of ADHD, any subtype.

Healthy Control Participants:

The participant must have no current DSM Axis I psychiatric disorder.

All Participants:

Participants must provide assent and a legal guardian must provide consent.
The participant is male or female and between 6 - 17 years of age and in good physical health.
Girls of childbearing potential must have a negative urine pregnancy test and, if sexually active, must be using adequate contraception.
The participant is English speaking.

Exclusion Criteria:

ADHD Participants:

The participant has a current comorbid DSM Axis I psychiatric diagnosis or other symptomatic manifestations that, in the opinion of the study doctor, will contraindicate lisdexamfetamine or guanfacine treatment or confound safety assessments.
The participant meets DSM-5 criteria for current substance abuse and/or dependence.
The participant is currently taking or has taken within the past 4 months, a psychotropic medication.
The participant has a documented allergy or intolerance to lisdexamfetamine or guanfacine products.
The participant has a diagnosis or a history of cardiovascular disease or any other serious medical illness.
The participant is pregnant or lactating.
The participant is actively suicidal.
MRI contraindications (e.g., irremovable metal on the body, pacemaker, braces)
The participant has a full-scale intelligence quotient (IQ) less than 70.
The participant has a history of seizure (except febrile seizure).

Healthy Controls:

The participant meets DSM criteria for current substance abuse and/or dependence.
The participant is currently taking a psychotropic medication.
The participant has a history of a serious medical illness.
The participant is pregnant or lactating.
MRI contraindications (e.g., irremovable metal on the body, pacemaker, braces)
The participant has a full-scale intelligence quotient (IQ) less than 70.
The participant has a history of seizure (except febrile seizure).
Intervention: Volasertib
Trial phase: Phase 1
SMILES: CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: 12 milligram (mg) solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).
Eligibility criteria:
Inclusion criteria:

Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
Age 18 years or older
Written informed consent consistent with ICH-GCP and local legislation
Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2

Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia)

The 18 additional patients recruited at the MTD must also meet the following criterion:

Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

Exclusion criteria:

Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Pregnancy or breastfeeding
Active infectious disease or known chronic Hepatitis B/Hepatitis C infection
Clinical evidence of active brain or leptomeningeal disease during the past 12 months
Second malignancy currently requiring active therapy
Absolute neutrophil count less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)
Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)
Known history of relevant QT-prolongation, e.g. long QT-syndrome
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.
Patients unable to comply with the protocol
Active alcohol or drug abuse
Intervention: Volasertib
Trial phase: Phase 1
SMILES: CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: 24 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).
Eligibility criteria:
Inclusion criteria:

Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
Age 18 years or older
Written informed consent consistent with ICH-GCP and local legislation
Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2

Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia)

The 18 additional patients recruited at the MTD must also meet the following criterion:

Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

Exclusion criteria:

Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Pregnancy or breastfeeding
Active infectious disease or known chronic Hepatitis B/Hepatitis C infection
Clinical evidence of active brain or leptomeningeal disease during the past 12 months
Second malignancy currently requiring active therapy
Absolute neutrophil count less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)
Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)
Known history of relevant QT-prolongation, e.g. long QT-syndrome
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.
Patients unable to comply with the protocol
Active alcohol or drug abuse
Intervention: Volasertib
Trial phase: Phase 1
SMILES: CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: 75 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).
Eligibility criteria:
Inclusion criteria:

Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
Age 18 years or older
Written informed consent consistent with ICH-GCP and local legislation
Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2

Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia)

The 18 additional patients recruited at the MTD must also meet the following criterion:

Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

Exclusion criteria:

Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Pregnancy or breastfeeding
Active infectious disease or known chronic Hepatitis B/Hepatitis C infection
Clinical evidence of active brain or leptomeningeal disease during the past 12 months
Second malignancy currently requiring active therapy
Absolute neutrophil count less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)
Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)
Known history of relevant QT-prolongation, e.g. long QT-syndrome
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.
Patients unable to comply with the protocol
Active alcohol or drug abuse
Intervention: Paclitaxel
Trial phase: Phase 2
ATC code: L01CD01 | L01CD51
SMILES: CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 69
Group description: Patients will be administered pre-operatively over 12 weeks either:

Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule
Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule

Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:

Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)

Paclitaxel: Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.

Radiation therapy: Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
Eligibility criteria:
Inclusion Criteria:

Biopsy proven locally-advanced breast cancer: IIB, IIIA, and IIIB
Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes
Measureable disease required
Adequate laboratory values:

Hgb > 10 ANC > 1500 Platelets > 150,000 Creatinine < 1.5 Liver function < 3x normal

Patient ≥ 18 years of age
Medically and psychologically able to comply with all study requirements
ECOG performance score 0-1
CT chest, abdomen, and pelvis performed
Mammogram or USG performed
Signed informed consent

Exclusion Criteria:

Breast cancer patients with Stage 0, Stage I, or Stage IIA
Previous XRT or chemotherapy
Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes
Pregnancy
Inflammatory breast cancer
Patients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medications
Patients who are found to have a cancer positive for the marker HER-2/neu (applies only to NYU Tisch and Bellevue sites)
Intervention: SULFUR
Trial phase: Phase 4
ATC code: D10AB02 | D11AC08
SMILES: S1SSSSSSS1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:

In adults, to assist in the:

localization of lymph nodes draining a primary tumor in patients with
breast cancer or malignant melanoma when used with a hand-held gamma counter.
evaluation of peritoneovenous (LeVeen) shunt patency in adults.
Eligibility criteria:
Inclusion Criteria:

The subject must be female and 18 years of age or older.
The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer
The subject must have a diagnosis of primary breast cancer.
The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.
The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2
The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study

Exclusion Criteria:

The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.
The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.
The subject has a positive pregnancy test or is lactating.
The subject has had prior surgery to the indicated breast or axilla.
Intervention: Chlordiazepoxide
Trial phase: Not Applicable
ATC code: N05BA02
SMILES: CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Control (Intra-operative administration of opioids, other than methadone)

Control (Intra-operative administration of opioids, other than methadone): Intra-operative administration of opioids, other than methadone
Eligibility criteria:
Inclusion Criteria:

Age 18-65 years
Undergoing general anesthesia and moderately painful, ambulatory surgical procedures with anticipated overnight, postop hospital stay of < 24 hours
Signed, written, informed consent

Exclusion Criteria:

History of or known liver or kidney disease.
Females who are pregnant or nursing.
Opioid tolerant patients (e.g. preoperative methadone therapy or use of fentanyl transdermal patches)
History of allergy to methadone
Intervention: Cycloserine
Trial phase: Early Phase 1
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, for 8 weeks.
Eligibility criteria:
Inclusion Criteria:

Carriers of a triplication in the glycine decarboxylase gene

Exclusion Criteria:

Not carriers of a triplication in the glycine decarboxylase gene
Intervention: Cycloserine
Trial phase: Early Phase 1
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.

D-cycloserine: Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
Eligibility criteria:
Inclusion Criteria:

Carriers of a triplication in the glycine decarboxylase gene

Exclusion Criteria:

Not carriers of a triplication in the glycine decarboxylase gene